Dr. Wasim Maziak, PhD, MD
Claim this profileFlorida International University
Studies Vaping
Studies Addiction
3 reported clinical trials
7 drugs studied
Affiliated Hospitals
Clinical Trials Wasim Maziak, PhD, MD is currently running
Menthol-Flavored E-Cigarettes
for Vaping
The use of electronic nicotine delivery systems (ENDS; e-cigarettes) has reached epidemic levels among young people in the United States (US). ENDS heat and vaporize a nicotine-containing liquid to produce an inhalable aerosol mist. While generally considered less harmful than combustible cigarettes, ENDS use exposes users to dependence-producing nicotine and respiratory and cardiovascular toxicants such as aldehydes. Flavor is a major factor in getting young people to use ENDS, thus limiting flavors to menthol and tobacco for prefilled cartridge ENDS "pod mods" was the first major action taken by the FDA to reduce the spread of ENDS among young people. Menthol flavor, however, can present a potential risk given its increasing popularity among young people in the US, and its puffing and nicotine-enhancing properties. Yet, the extent of menthol's ability to affect users' experience and puffing patterns, and how these affect dependence, exposure to toxicants, and clinical outcomes continue to be understudied. Such evidence will be critical to the FDA's ability to set further regulatory standards to reduce ENDS potential harm. The investigators will conduct a 2x2 (pre-post x menthol vs. tobacco flavor) crossover clinical lab study. The investigator will recruit current/past month ENDS users (n=250, 21-35 yrs), who will attend two sessions and use their ENDS once with menthol and once with tobacco flavors. The proposed studies will answer two key regulatory questions consistent with FDA's focus on the role of flavor in tobacco products' addiction and toxicity; 1) compared to tobacco flavor, does menthol carry additional risk by enhancing puffing, abuse liability, and toxicant exposure in ENDS users, and; 2) is this effect more pronounced among high dependence compared to other users. Other outcomes such as harm perception, satisfaction, clinical responses, intention to use or quit, and group comparisons such as according to race, and sex will allow the FDA a comprehensive assessment of the pros and cons of regulating mentholated ENDS for different segments of the society. Such evidence will help advance FDA regulatory policies with the potential to reduce ENDS harm.
Recruiting1 award N/A6 criteria
Health Warning Labels
for Hookah Smoking
Waterpipe (WP) smoking has become one of the leading tobacco use methods among youth in Florida. The impact of this dramatic rise is amplified by the mounting evidence of WP addictive and harmful nature, as well as the lag of policy response to it. Evidence suggests WP use leads to nicotine addiction, and increases the risk of lung cancer, heart and respiratory disease and exposure to secondhand smoke. The spread of WP use among youth has been fueled by a misperception of reduced-harm compared to cigarettes. Health Warning Labels (HWLs) represent one of the most successful tobacco control strategies to communicate smoking- related risks, and studies have consistently shown that HWLs are associated with a decrease in smoking rates and smoking-related morbidity and mortality. Therefore, communicating WP risks to young people through HWLs has been identified as a priority by major health bodies in the US including the FDA. Using the Delphi method among international tobacco control experts, our team has developed a set of 12 WP HWLs corresponding to 4 health themes; health risks/addiction, harm to others, WP-specific harm, WP harm compared to cigarettes. Building on this work, and using a mixed- method approach incorporating qualitative and quantitative research, the investigators propose to: Aim 1: Adapt the 12 HWLs to young WP smokers in Florida using exploratory focus groups. Aim 2: Test in a clinical lab experiment the performance of the top 4 HWLs on the WP device compared to no-HWL/control on harm perception, intention to quit, and toxicant exposure (Carbon monoxide (CO), nicotine, oxidative stress). Aim 3: Use the knowledge obtained to advocate for the adoption of WP-HWLs policies and disseminate information about WP harmful effects to young people in Florida and nationally. Communicating WP risks through HWLs promises to reduce WP use and WP-related morbidly and mortality among young adults in Florida. This pioneering work will inform the FDA and public health advocates on the potential of WP-HWLs policies and provide a model for other states to respond to the WP epidemic.
Recruiting1 award N/A6 criteria
More about Wasim Maziak, PhD, MD
Clinical Trial Related2 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Wasim Maziak, PhD, MD has experience with
- 5% Nicotine
- 0% Nicotine
- 3% Nicotine
- Test Without Health Warning Label (no-HWL)
- Test Health Warning Label (HWL)
- Tobacco-flavored E-cigarette
Breakdown of trials Wasim Maziak, PhD, MD has run
Harm Perception
Quitting Smoking
Hookah Smoking
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Wasim Maziak, PhD, MD specialize in?
Wasim Maziak, PhD, MD focuses on Vaping and Addiction. In particular, much of their work with Vaping has involved treating patients, or patients who are undergoing treatment.
Is Wasim Maziak, PhD, MD currently recruiting for clinical trials?
Yes, Wasim Maziak, PhD, MD is currently recruiting for 3 clinical trials in Miami Florida. If you're interested in participating, you should apply.
Are there any treatments that Wasim Maziak, PhD, MD has studied deeply?
Yes, Wasim Maziak, PhD, MD has studied treatments such as 5% nicotine, 0% nicotine, 3% nicotine.
What is the best way to schedule an appointment with Wasim Maziak, PhD, MD?
Apply for one of the trials that Wasim Maziak, PhD, MD is conducting.
What is the office address of Wasim Maziak, PhD, MD?
The office of Wasim Maziak, PhD, MD is located at: Florida International University, Miami, Florida 33199 United States. This is the address for their practice at the Florida International University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.